(12) United States Patent (10) Patent No.: US 9,683,047 B2 Smith Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO9683 047B2 (12) United States Patent (10) Patent No.: US 9,683,047 B2 Smith et al. (45) Date of Patent: Jun. 20, 2017 (54) METHODS FOR TREATING PROGRESSIVE (56) References Cited MULTIPLE SCLEROSIS U.S. PATENT DOCUMENTS (71) Applicant: Genentech, Inc., South San Francisco, 3,773.919 A 11/1973 Boswell et al. CA (US) 4,120,649 A 10/1978 Schechter 4.485,045 A 11/1984 Regen (72) Inventors: Craig Smith, Seattle, WA (US); Peter $3.5 A g 3. S.tringfellow i. et al.1 S. Chin, San Francisco, CA (US) 4,676.980 A 6/1987 Segal et al. 4,816,567 A 3/1989 Cabilly et al. (73) Assignee: Genentech, Inc., South San Francisco, 4,861,579 A 8/1989 Meyer, Jr. et al. CA (US) 4,892,538 A 1/1990 Aebischer et al. 4,975,278 A 12/1990 Senter et al. (*) Notice: Subject to any disclaimer, the term of this 5,013,556 A 5/1991 Woodle et al. 5,114,721 A 5/1992 Cohen et al. patent is extended or adjusted under 35 5,208,020 A 5/1993 Chari et al. U.S.C. 154(b) by 0 days. 2,229,275 A 7/1993 Goroff 5,283,187 A 2f1994 Aebischer et al. (21) Appl. No.: 15/201,300 5,500,362 A 3, 1996 Robinson et al. 9 5,545,807 A 8, 1996 Surani et al. 5,565,332 A 10/1996 Hoogenboom et al. (22) Filed: Jul. 1, 2016 5,567,610 A 10/1996 Borrebaecket al. 5,571,894 A 11/1996 Wells et al. (65) Prior Publication Data 5,573,905 A 11/1996 Lerner et al. 5,587,458 A 12/1996 King et al. US 2017/OO29522 A1 Feb. 2, 2017 5,589,369 A 12/1996 Seidman et al. 5,591,669 A 1/1997 Krimpenfort et al. 5,595,721 A 1/1997 Kaminski O O 5,641,870 A 6/1997 Rinderknecht et al. Related U.S. Application Data 5,648,267 A T/1997 Reff 5,677, 180 A 10, 1997 Robinson et al. (60) Continuation of application No. 14,702,583, filed on 5,693,780 A 12/1997 Newman et al. May 1, 2015, now abandoned, which is a continuation 5,721, 108 A 2, 1998 Robinson et al. of application No. 14/049,130, filed on Oct. 8, 2013, 5,731, 168 A 3, 1998 Carter et al. now abandoned, which is a continuation of 27C A SE Reson et al application No. 13/414,698, filed on Mar. 7, 2012, 5,730,377 A 4/1998 Presta now abandoned, which is a division of application 5,776.456 A 7/1998 Anderson et al. No. 12/561,131, filed on Sep. 16, 2009, now 5,821,337 A 10 1998 Carter et al. abandoned. (Continued) FOREIGN PATENT DOCUMENTS (60) Provisional application No. 61/097.464, filed on Sep. 16, 2008. CA 2O19559 C 12/1990 s CN 1420129. A 5, 2003 (51) Int. Cl. (Continued) C07K 6/28 (2006.01) GOIN 33/68 (2006.01) OTHER PUBLICATIONS A6 IK 39/00 (2006.01) Montalban et al., Ocrelizumab versus Placebo in Primary Progres G06Q 99/00 (2006.01) sive Multiple Sclerosis, Jan. 19, 2017. The New England Journal of Medicine 376(3):209-220.* A6B 5/55 (2006.01) Albert, D.A. et al. (Dec. 2003). “A Phase I Trial of Rituximab A 6LX 39/395 (2006.01) (Anti-CD20) for Treatment of Systemic Lupus Erythematosus.” A6 IK 9/00 (2006.01) Abstract LB9, Arthritis and Rheumatism 48(12): 3659. A6 IK 45/06 (2006.01) Anderson, D.W. et al. (Mar. 1992). “Revised Estimate of the (52) U.S. Cl. Prevalence of Multiple Sclerosis in the United States.” Ann Neu CPC .......... C07K 16/2887 (2013.01); A61 B 5/055 Anderson,3 (23. K.C. et al.(1984). “Expression of Human B Cell-Asso (2013.01); A61K 9/0019 (2013.01); A61 K ciated Anti 39/00 (2013.0). A61K.39/3955 (2013.01); B cell Differentiation.gens on Leukemias Blood and 66.424.433. Lymphomas: A Model of Human A61K 45/06 (2013.01); G0IN 33/686 (Continued) (2013.01); G06Q 99/00 (2013.01); A61 K 2039/505 (2013.01); A61K 2039/507 Primary Examiner — John Ulm (2013.01); A6 IK 2039/545 (2013.01); A61 K (74) Attorney, Agent, or Firm — Morrison & Foerster 2039/55 (2013.01); C07K 2317/24 (2013.01); LLP C07K 231 7/565 (2013.01); C07K 2317/76 (2013.01); G0IN 2800/52 (2013.01); G0IN (57) ABSTRACT 2800/7095 (2013.01) The present invention concerns methods for treating pro (58) Field of Classification Search gressive multiple Sclerosis (MS) in a patient, and an article None of manufacture with instructions for Such use. See application file for complete search history. 29 Claims, 18 Drawing Sheets US 9,683,047 B2 Page 2 (56) References Cited 2003/0219433 A1 11/2003 Hansen et al. 2003/02198.18 A1 11/2003 Bohen et al. U.S. PATENT DOCUMENTS 2003/0220268 A1 11/2003 Makino et al. 2004/0072290 A1 4/2004 Umana et al. 5.843,398 A 12, 1998 Kaminski et al. 2004/OO72749 A1 4/2004 Zochoer et al. 5.843.439 A 12/1998 Anderson et al. 2004/0093.621 A1 5/2004 Shitara et al. 5,849.898. A 12, 1998 seed et al. 2004.0109865 A1 6, 2004 Niwa et al. 6015.543 A 1/2000 Kaminski et al. 2004/0110282 A1 6/2004 Kanada et al. 6017.733 A 1, 2000 Reff 2004/0110704 A1 6/2004 Yamane et al. 6,090,365 A 7/2000 Kaminski et al. 2004/O132140 A1 7/2004 Satoh et al. 6.130767 A 9, 2000 Robinson et al. 2004/01673 19 A1 8/2004 Teeling et al. 6.155730. A 12/2000 Reff 2004/019 1256 A1 9/2004 Raju 6,171,586 B1 1/2001 fam et al. 2004/0202658 A1 10/2004 Benyunes 6,183,744 B1 2/2001 Goldenberg 2004/0213784 A1 10/2004 Grillo-Lopez et al. 6,194.551 B1 2/2001 Idusogie et al. 2004/022885.6 A1 11, 2004 Presta 6,224,866 B1 5, 2001 Barbera-Guillem 2004/0235848 A1 11/2004 OkuZumi et al. 6.242,195 B1 6/2001 Idusogie et al. 2004/025915.0 A1 12/2004 Nakamura et al. 6,267,958 B1 7/2001 Andya et al. 2005, OO18206 A1 1/2005 H11 6,287,537 B1 9/2001 Kaminski et al. 2005/0O25764 A1 2/2005 Watkins et al. 6,306,393 B1 10/2001 Goldenberg 2005, OO31613 A1 2/2005 Nakamura et al. 6.348.463 B1 2/2002 Head et al. 2005, OO32130 A1 2/2005 Beresini et al. 6,368.596 B1 4/2002 Ghetie et al. 2005.00536O2 A1 3, 2005 Brunetta 6,369,229 B1 4/2002 Headeral. 2005, OO695.45 A1 3, 2005 Carr et al. 6.399,061 B1 6/2002 Anderson et al. 2005/007.9174 A1 4/2005 Barbera-Guillem et al. 6.410391 B1 6/2002 Zeisacher 2005/0095243 A1 5.2005 Chan et al. 6,455,043 B1 9/2002 Grillo-Lopez 2005/0106.108 A1 5/2005 Leung et al. 6,528,624 B1 3/2003 Idusogie et al. 2005/O112060 A1 5.2005 White 6,538,124 B1 3/2003 Idusogie et al. 2005/0118174 A1 6, 2005 Presta 6565,827 B1 5/2003 Kaminski et al. 2005, 0123540 A1 6/2005 Hanna et al. 6,602,684 B 82003 Umana et al. 2005, 0123546 A1 6/2005 Umana et al. 6,652,852 B 11/2003 Robinson et al. 2005/0136049 A1 6/2005 Ledbetter et al. 6677.339 B2 i? 2004 headeral 2005, 0160 108 A1 7, 2005 Charlet et al. 6,682,734 B1 1/2004 Anderson et al. 2005, 0163775 A1 7, 2005 Chan et al. 6.737,056 B1 5, 2004 Presta 2005/0175614 A1 8, 2005 Ledbetter et al. 6.846,476 B2 1/2005 White 2005/0180970 A1 8/2005 Ledbetter et al. 6,893,625 B1 5, 2005 Robinson et al. 2005/O180972 A1 8, 2005 Wahl et al. 6.896.885 B2 5/2005 Hanna 2005. O180975 A1 8/2005 Hanna 6,897,044 B 5/2005 Brasiawsky et al. 2005/0186205 A1 8/2005 Anderson et al. 6,991,790 B1 1/2006 Lam et al. 2005, 0186216 A1 8, 2005 Ledbetter et al. 7,074,403 B1 7/2006 Goldenberg et al. 2005, 0191297 A1 9, 2005 Brunetta 7,122,637 B2 10, 2006 Presta 2005, 0191300 A1 9/2005 Goldenberg et al. 7.15164 B2 12/2006 Hansen et al. 2005/0202012 A1 9, 2005 Ledbetter et al. 7,799,900 B2 9/2010 Adams et al. 2005/0202023 A1 9, 2005 Ledbetter et al. 2001/0018041 A1 8/2001 Hanna et al. 2005/0202028 A1 9, 2005 Ledbetter et al. 2001/0056066 Al 12/2001 Bugelski et al. 2005/0202534 A1 9, 2005 Ledbetter et al. 2002, 0004587 A1 1/2002 Miller et al. 2005/0233382 A1 10, 2005 Presta 2002/0006404 A1 1/2002 Hanna et al. 2005/0255527 A1 1 1/2005 Yang et al. 2002fOOO9427 A1 1/2002 Wolin et al. 2005/0271658 A1 12/2005 Brunetta et al. 2002/0009444 A1 1/2002 Grillo-Lopez 2005/0272916 A1 12/2005 Hanai et al. 2002fOO 12665 A1 1/2002 Hanna 2005/0276803 A1 12/2005 Chan et al. 2002fOO28178 A1 3/2002 Hanna et al.